DE69228698D1 - HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG - Google Patents

HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG

Info

Publication number
DE69228698D1
DE69228698D1 DE69228698T DE69228698T DE69228698D1 DE 69228698 D1 DE69228698 D1 DE 69228698D1 DE 69228698 T DE69228698 T DE 69228698T DE 69228698 T DE69228698 T DE 69228698T DE 69228698 D1 DE69228698 D1 DE 69228698D1
Authority
DE
Germany
Prior art keywords
hbsag
plasmodium
hybrid protein
protein
falciparum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69228698T
Other languages
English (en)
Other versions
DE69228698T2 (de
Inventor
Wilde Michel De
Joseph Smithkline Beecha Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919124390A external-priority patent/GB9124390D0/en
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Application granted granted Critical
Publication of DE69228698D1 publication Critical patent/DE69228698D1/de
Publication of DE69228698T2 publication Critical patent/DE69228698T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DE69228698T 1991-11-16 1992-11-11 HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG Expired - Lifetime DE69228698T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919124390A GB9124390D0 (en) 1991-11-16 1991-11-16 Vaccines
US84269492A 1992-02-27 1992-02-27
PCT/EP1992/002591 WO1993010152A1 (en) 1991-11-16 1992-11-11 HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG

Publications (2)

Publication Number Publication Date
DE69228698D1 true DE69228698D1 (de) 1999-04-22
DE69228698T2 DE69228698T2 (de) 1999-09-16

Family

ID=26299880

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228698T Expired - Lifetime DE69228698T2 (de) 1991-11-16 1992-11-11 HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG

Country Status (16)

Country Link
EP (1) EP0614465B1 (de)
JP (2) JP3954643B2 (de)
KR (1) KR100251505B1 (de)
AT (1) ATE177755T1 (de)
AU (2) AU2927892A (de)
CA (1) CA2123612C (de)
DE (1) DE69228698T2 (de)
DK (1) DK0614465T3 (de)
ES (1) ES2129461T3 (de)
GR (1) GR3029717T3 (de)
HK (1) HK1012405A1 (de)
MX (1) MX9206574A (de)
NZ (1) NZ245114A (de)
PT (1) PT101052B (de)
SG (1) SG48390A1 (de)
WO (1) WO1993010152A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
SK279188B6 (sk) 1992-06-25 1998-07-08 Smithkline Beecham Biologicals S.A. Vakcínová kompozícia spôsob jej prípravy a použiti
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
GB9915204D0 (en) * 1999-06-29 1999-09-01 Smithkline Beecham Biolog Vaccine
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
CA2507915C (en) 2002-12-17 2013-07-02 Crucell Holland B.V. Recombinant viral-based malaria vaccines
AU2003244053A1 (en) * 2003-06-03 2005-01-21 Shanghai Centre Of Research And Development Of New Drugs A fusion protein suitable to be expressed high effectively and the production method thereof
ATE497974T1 (de) 2003-07-21 2011-02-15 Transgene Sa Multifunktionelle cytokine
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
BRPI0518146A (pt) * 2004-10-14 2008-10-28 Crucell Holland Bv kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
CA2605179A1 (en) * 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics, Inc. Expressing hepatitis b virus surface antigen for vaccine preparation
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
SG173363A1 (en) * 2006-07-18 2011-08-29 Glaxosmithkline Biolog Sa Vaccines for malaria
GB0614254D0 (en) * 2006-07-18 2006-08-30 Smithkline Beecham Biolog Vaccine
MX2009002561A (es) 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2673046T3 (es) 2006-09-26 2018-06-19 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
KR101151202B1 (ko) 2006-10-12 2012-06-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 수중유 에멀젼 애주번트를 포함하는 백신
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
US20100055166A1 (en) 2007-03-02 2010-03-04 Gerald Hermann Voss Novel method and compositions
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
US9066899B2 (en) 2007-08-13 2015-06-30 Glaxosmithkline Biologicals Sa Vaccines
AR069936A1 (es) * 2007-12-24 2010-03-03 Glaxosmithkline Biolog Sa Vacunas contra la malaria que comprenden una proteina de fusion derivada de proteina cs de plasmodium vivax y un antigeno s de hepatitis b
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
US9555089B2 (en) 2009-08-18 2017-01-31 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
CA2832307A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
RS58868B1 (sr) 2012-02-07 2019-08-30 Infectious Disease Res Inst Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
RU2705301C2 (ru) 2012-02-16 2019-11-06 Влп Терапьютикс, Ллк Композиция вирусоподобных частиц
US9555099B2 (en) 2012-05-16 2017-01-31 Immune Design Corp. Vaccines for HSV-2
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
JPWO2014103608A1 (ja) 2012-12-25 2017-01-12 一般財団法人化学及血清療法研究所 ＨＰＶ／ＨＢｓキメラタンパク質を有効成分とするＨＰＶ感染症及び／又はＢ型肝炎用ワクチン
ES2847930T3 (es) 2013-01-07 2021-08-04 Mucosal Vaccine Tech Llc Vacunas terapéuticas para el tratamiento de las infecciones por el virus del herpes simple de tipo 2
US9821046B2 (en) 2013-01-21 2017-11-21 Oxford University Innovation Limited Composition and uses thereof
BE1022174B1 (fr) 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
KR102494564B1 (ko) * 2013-06-03 2023-01-31 브이엘피 테라퓨틱스 인코포레이티드 말라리아 백신
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
EP2873728A1 (de) 2013-11-18 2015-05-20 Institut Pasteur Subunit-Impfstoff-Plattform auf Grundlage multimerer Ribonukleoproteine mit Nukleoproteinen eines nichtsegmentierten Negativstrang-RNA-Virus als Träger von heterologen Polypeptiden
EP3089754B1 (de) 2013-12-31 2021-04-21 Infectious Disease Research Institute Impfstoffformulierungen mit einzelphiole
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
PL3188755T3 (pl) 2014-09-01 2021-01-25 International Centre For Genetic Engineering And Biotechnology Szczepionka
CN106687590B (zh) 2014-09-11 2021-08-03 Vlp治疗公司 黄热病毒病毒样颗粒
WO2016184784A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides including binding domain of plasmodium falciparum proteins (cbp1 and cbp2) to chemokine cx3cl1
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
HUE059605T2 (hu) 2016-05-16 2022-11-28 Access To Advanced Health Inst TLR agonista tartalmú készítmény és használati eljárások
WO2017200957A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Pegylated liposomes and methods of use
US11173126B2 (en) 2016-06-01 2021-11-16 Infectious Disease Research Institute Nanoalum particles comprising a PAA sizing agent
WO2018104313A1 (en) 2016-12-07 2018-06-14 Glaxosmithkline Biologicals Sa Novel process
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
BR112019026615B1 (pt) 2017-06-15 2022-08-02 Infectious Disease Research Institute Carreadores lipídicos nanoestruturados e emulsões estáveis e usos dos mesmos
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
US20220177558A1 (en) 2019-03-25 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
KR20220125149A (ko) 2019-05-25 2022-09-14 액세스 투 어드밴스드 헬스 인스티튜트 애주번트 백신 에멀션을 분무 건조시키기 위한 조성물 및 방법
CA3142300A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
CA3174411A1 (en) 2020-09-04 2022-03-10 Ryan M. Kramer Co-lyophilized rna and nanostructured lipid carrier
US11655290B2 (en) 2021-06-17 2023-05-23 Atreca, Inc. Anti-CSP antibodies
EP4169513A1 (de) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Hilfsstoffzusammensetzung enthaltend sting agonisten
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175261B1 (de) * 1984-09-12 1991-12-11 Chiron Corporation Hybridpartikel-Immunogene
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
ZA88488B (en) * 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
US4886782A (en) * 1987-02-26 1989-12-12 The United States Of America As Represented By The Department Of Health And Human Services Malarial immunogen
DE10299017I2 (de) * 1987-06-22 2005-05-25 Medeva Holdings Bv Hepatitis-B-Oberfl{chenantigen enthaltendes Peptid.
GB8812214D0 (en) * 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5028425A (en) * 1988-07-07 1991-07-02 The United States Of America As Represented By The Department Of Health And Human Services Synthetic vaccine against P. falciparum malaria

Also Published As

Publication number Publication date
AU2927892A (en) 1993-06-15
MX9206574A (es) 1993-05-01
NZ245114A (en) 1995-07-26
DE69228698T2 (de) 1999-09-16
EP0614465A1 (de) 1994-09-14
CA2123612C (en) 2002-06-25
HK1012405A1 (en) 1999-07-30
ATE177755T1 (de) 1999-04-15
DK0614465T3 (da) 1999-09-27
WO1993010152A1 (en) 1993-05-27
JP4241846B2 (ja) 2009-03-18
KR100251505B1 (ko) 2000-05-01
JP2007209343A (ja) 2007-08-23
ES2129461T3 (es) 1999-06-16
PT101052A (pt) 1994-01-31
AU712409B2 (en) 1999-11-04
JP3954643B2 (ja) 2007-08-08
JPH07501213A (ja) 1995-02-09
CA2123612A1 (en) 1993-05-27
GR3029717T3 (en) 1999-06-30
PT101052B (pt) 1999-10-29
SG48390A1 (en) 1998-04-17
AU1471797A (en) 1997-06-12
EP0614465B1 (de) 1999-03-17

Similar Documents

Publication Publication Date Title
DE69228698D1 (de) HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG
DK0835663T3 (da) Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
BR9206131A (pt) Hepatite C: diagnóstico e vacinas
DK0759935T3 (da) Rekombinant papillomavirus L1
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
DE69433007D1 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
DZ1706A1 (fr) Vaccin contre le virus de l'hepatite a.
DE69232460D1 (de) Die ansteckung blockierende malariaimpfstoffe
FI952171A0 (fi) Hepatiitti B-pinta-antigeeneille aktiivisten ihmisen monoklonaalisten vasta-aineiden tuotto
EP0542753A4 (en) Epitopes of the pre-s region of hepatitis b virus surface antigen
ZA888580B (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
DE9117146U1 (de) Impfstoffe gegen virale Antigene
ATE177010T1 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie
KR880701732A (ko) 플라스모듐 팔시파룸(Plasmodium falciparum)의 분열체 표면 항원
CS578887A1 (en) Inactivated antigen of cattle's mucosal disease's virus
BR1100913A (pt) Vacinas combinadas compreendendo o antìgeno superficial da hepatite b e outros antìgenos
ZA883365B (en) Newcastle disease virus vaccine and method for the application thereof
DE69033316T2 (de) Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C Virus
IT9019800A0 (it) Composti immunogenici e loro impiego per la preparazione di vaccini sintetici geneticamente non ristretti per la determinazione immunoenzimatica di anticorpi anti-sporozoita di plasmodium malariae

Legal Events

Date Code Title Description
R071 Expiry of right

Ref document number: 614465

Country of ref document: EP